Guillain-Barré syndrome after bortezomib therapy in a child with relapsed acute lymphoblastic leukemia.
Valeria CeolinRosita CennaFrancesca ResenteManuela SpadeaFranca FagioliNicoletta BertorelloPublished in: Pediatric hematology and oncology (2021)
A 12-year-old male being treated for a high-risk relapsed T-acute lymphoblastic leukemia presented progressive weakness and numbness of both legs after having received a chemotherapy regimen that included bortezomib. Diagnosis of acute Guillain-Barré syndrome-like inflammatory demyelinating polyneuropathy was made following clinical examination, cerebrospinal fluid analysis, electrodiagnostic studies, magnetic resonance imaging, and serum immunoglobulin antibodies to anti-ganglioside. Intravenous immunoglobulin treatment was started, resulting in complete clinical recovery. Although in rare cases, Guillain-Barré syndrome after bortezomib therapy has been reported; this paper suggests that GBS may occur when bortezomib is administered and high‑dose intravenous immunoglobulin lead to a resolution of the symptoms.
Keyphrases
- acute lymphoblastic leukemia
- multiple myeloma
- high dose
- magnetic resonance imaging
- allogeneic hematopoietic stem cell transplantation
- newly diagnosed
- cerebrospinal fluid
- case report
- low dose
- mental health
- multiple sclerosis
- stem cell transplantation
- acute myeloid leukemia
- diffuse large b cell lymphoma
- squamous cell carcinoma
- computed tomography
- magnetic resonance
- oxidative stress
- extracorporeal membrane oxygenation
- bone marrow
- intensive care unit
- drug induced
- radiation therapy
- sleep quality
- single molecule